STAINES-UPON-THAMES, United
Kingdom, Feb. 14, 2020
/PRNewswire/ -- Mallinckrodt
plc (NYSE: MNK), a global biopharmaceutical company, announced
today that it will report fourth quarter and fiscal 2019 earnings
results for the period ending Dec. 27, 2019 on Tuesday, Feb. 25, 2020.
A conference call for investors will begin at 8:30
a.m. Eastern. The call can be accessed in three ways:
- At
the Mallinckrodt website: http://www.mallinckrodt.com/investors.
- By telephone: For both listen-only participants and those who
wish to take part in the question-and-answer portion of the call,
the telephone dial-in number in the U.S. is (877) 359-9508. For
participants outside the U.S., the dial-in number is (224)
357-2393. Callers will need to provide the Conference ID of
4168459.
- Through an audio replay: A replay of the call will be available
beginning at 11:30 a.m. Eastern Time on Tuesday,
Feb. 25, 2020, and ending at 11:30 a.m. Eastern Time
on Tuesday, March 10, 2020. Dial-in numbers for U.S.-based
participants are (855) 859-2056 or (800) 585-8367. Participants
outside the U.S. should use the replay dial-in number of (404)
537-3406. All callers will be required to provide the Conference ID
of 4168459.
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of
multiple wholly owned subsidiaries that develop, manufacture,
market and distribute specialty pharmaceutical products and
therapies. The company's Specialty Brands reportable segment's
areas of focus include autoimmune and rare diseases in specialty
areas like neurology, rheumatology, nephrology, pulmonology and
ophthalmology; immunotherapy and neonatal respiratory critical care
therapies; analgesics and gastrointestinal products. Its Specialty
Generics reportable segment includes specialty generic drugs and
active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution
of important company information, such as press releases, investor
presentations and other financial information. It also uses its
website to expedite public access to time-critical information
regarding the company in advance of or in lieu of distributing a
press release or a filing with the U.S. Securities and
Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. © 2020
Mallinckrodt. 02/2020
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-fourth-quarter-and-fiscal-2019-301005205.html
SOURCE Mallinckrodt plc